NEW YORK – Labcorp and Ultima Genomics said Tuesday that they are collaborating on next-generation sequencing-based cancer testing.
Labcorp will use Ultima's UG100 sequencer and ppmSeq technology for minimal residual disease (MRD) testing in patients with early-stage solid tumors and is exploring the sequencer's use in other applications. Ultima will support Labcorp in its assay development. Financial and other terms of the deal were not disclosed.
In a statement, the firms said combining Labcorp's Plasma Detect circulating tumor DNA MRD test with the UG100 and ppmSeq technologies demonstrated "the ability to detect rare variants at extremely low limits, improved sensitivity and specificity, and more efficient, scalable, and cost-effective workflows."
"By combining Labcorp's leadership, testing capabilities, and expansive network with the accuracy, scalability, and cost-effectiveness of Ultima's technology, we can help transform oncology testing for pathologists, oncologists, and our biopharmaceutical partners," Shakti Ramkissoon, VP and medical lead for oncology at Labcorp, said in a statement. "Through this collaboration, Labcorp aims to drive increased efficiency, scalability, and cost-effectiveness."
In January, Ultima and Quest Diagnostics also announced a collaboration to develop new NGS-based clinical tests.